Codexis (CDXS) director Raymond De Vre awarded 66,350 stock options at $2.48

Rhea-AI Filing Summary

CODEXIS, INC. director Raymond De Vre received a grant of stock options covering 66,350 shares of common stock. The options have an exercise price of $2.48 per share and expire on June 17, 2036. The award vests in full on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, subject to his continued service as a director. Following this grant, De Vre holds 66,350 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider De Vre Raymond

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	66,350	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 66,350 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 66,350 options Exercise price: $2.48 per share Expiration date: June 17, 2036 +1 more

4 metrics

Options granted 66,350 options Director stock option award

Exercise price $2.48 per share Stock option strike price

Expiration date June 17, 2036 Option term end

Total options after grant 66,350 options Direct holdings following transaction

Key Terms

Stock Option (Right to Buy), exercise price, vests and becomes exercisable, annual stockholder meeting, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "2.4800""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vests and becomes exercisable financial

"This option vests and becomes exercisable with respect to all of the shares"

annual stockholder meeting financial

"on the earlier of the first anniversary of the date of grant or the next annual stockholder meeting"

An annual stockholder meeting is a yearly gathering where a company's owners (shareholders) receive updates on performance, vote on key issues like board members, executive pay and major corporate plans, and ask questions of management. Think of it as a company town hall where choices about oversight and direction are decided; outcomes can affect management accountability, corporate strategy and ultimately the value and risks of investors’ shares.

continued service financial

"subject to the director's continued service to the Company on such vesting date"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

De Vre Raymond

(Last) (First) (Middle)

C/O CODEXIS, INC.

200 PENOBSCOT DRIVE

(Street)

REDWOOD CITY CALIFORNIA 94063

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CODEXIS, INC. [ CDXS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.48	06/17/2026		A		66,350		(1)	06/17/2036	Common Stock	66,350	$0	66,350	D

Explanation of Responses:

1. This option vests and becomes exercisable with respect to all of the shares subject to the award on the earlier of the first anniversary of the date of grant or the next annual stockholder meeting, subject to the director's continued service to the Company on such vesting date.

	/s/ Georgia Erbez, as Attorney-in-Fact for Raymond De Vre	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did CODEXIS (CDXS) director Raymond De Vre report on this Form 4?

Raymond De Vre reported receiving a stock option grant for 66,350 shares. The award is a compensation-related grant and not an open-market share purchase or sale.

How many stock options did Raymond De Vre receive from Codexis (CDXS)?

He received options covering 66,350 shares of Codexis common stock. These are derivative securities giving him the right to buy shares at a fixed exercise price.

What is the exercise price of Raymond De Vre’s Codexis (CDXS) stock options?

The options have an exercise price of $2.48 per share. This is the price at which he may buy Codexis common stock once the options have vested and are exercisable.

When do Raymond De Vre’s Codexis (CDXS) options vest?

The options vest in full on the earlier of the first anniversary of the grant date or the next annual stockholder meeting. Vesting is conditioned on his continued service as a director through that date.

When do Raymond De Vre’s Codexis (CDXS) stock options expire?

These options expire on June 17, 2036. After the expiration date, any unexercised portion of the award can no longer be used to purchase Codexis common shares.

Does this Codexis (CDXS) Form 4 show any stock being bought or sold on the market?

No open-market buys or sells are reported. The filing shows a grant of stock options as compensation, rather than a market transaction in Codexis common stock.